Ovid Stock Surges on Surprise Q4 Profit Beat and $60M PIPE to Expand OV329 into New Seizure Indications
Ovid Therapeutics shares climbed after swinging to a surprise Q4 profit beat and raising $60 million via PIPE financing. Funds will expand OV329 development into tuberous sclerosis complex and infantile spasms.
